#United States #Chicago #AVEO Oncology #Tivozanib #ASCO 2026

AVEO Oncology to Present at ASCO 2026

AVEO Oncology, part of LG Chem, has recently announced that it will be presenting two notable studies at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place from May 29 to June 2, 2026, in Chicago, Illinois. This prestigious event reflects AVEO's ongoing dedication to advancing research and treatments within the oncology field.

Presentation Highlights

Study on Tivozanib

The first study shared by AVEO, titled "Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of tivozanib in patients with metastatic renal cell carcinoma (mRCC)," will be led by Dr. Robert Motzer from the Memorial Sloan Kettering Cancer Center. This study centers on the long-term effectiveness and safety of tivozanib, particularly for those battling mRCC. The presentation is scheduled for Sunday, May 31, 2026, from 9:00 AM to 12:00 PM CDT at Poster Board 34 during the Genitourinary Cancer session. With mRCC remaining a challenging area in cancer treatment, insights from this ongoing study promise to shape future therapeutic strategies.

FIERCE-HN Study

The second presentation is titled "FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab in combination with cetuximab in participants with recurrent or metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC)," spearheaded by Dr. Julie E. Bauman of the George Washington University Cancer Center. This significant study aims to evaluate the efficacy of ficlatuzumab in combination with cetuximab for patients facing HNSCC, a disease that often proves daunting to treat effectively. It will take place on Saturday, May 30, 2026, from 1:30 PM to 4:30 PM CDT at Poster Board 585b.

AVEO's Commitment to Oncology

AVEO is known for its relentless pursuit of delivering better treatment options for cancer patients. The company’s flagship product, FOTIVDA® (tivozanib), is currently marketed in the U.S. for adult patients with relapsed or refractory advanced renal cell carcinoma after two or more systemic therapies. The company continues to explore enhanced therapeutic combinations in RCC and is expanding its research into additional areas of high unmet medical needs, such as using ficlatuzumab for HPV-negative HNSCC patients and rilogrotug in cancer cachexia cases.

Strategic Partnership with LG Chem

AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. This partnership enables AVEO to leverage LG Chem’s extensive resources to accelerate the development of its therapies and broaden its focus on innovative cancer treatments. LG Chem itself is a global leader in chemicals, encompassing a wide spectrum from petrochemicals to advanced materials and life sciences, further illustrating the synergistic potential of this collaboration.

Looking Forward

Presenting at ASCO is a significant milestone for AVEO, allowing it to highlight its contributions to the oncology community and network with other leading professionals. As the event approaches, the company anticipates an engaging platform for discussions around its studies and potential advancements in cancer care. The outcomes of these studies could play a critical role in shaping future treatment protocols, providing hope for patients and healthcare professionals alike.

In conclusion, AVEO's participation in the ASCO 2026 Annual Meeting marks another step forward in its mission to improve cancer treatment options through rigorous research and innovation. The insights gained from these presentations could lead to significant advancements in how metastatic renal cell carcinoma and head and neck cancers are treated in the future.